POS6 ECONOMIC ANALYSIS: IBANDRONATE (BONVIVA®) IV INJECTION FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS (PMO) IN THE UK  by Cowell, W et al.
A380 Abstracts
senting net savings of €1123 per patient. Using rhBMP-2 in all
grades of tibia fracture resulted in an incremental cost of €134
per patient and a cost-effectiveness ratio of €3052/QALY. In
France, using rhBMP-2 for grade III open tibia fractures, and all
fractures resulted in cost savings of €2312, and €824 per patient,
respectively. When analyzed from the NHS perspective in the
UK, rhBMP-2 treatment for grade III open tibia fractures
resulted in a cost-effectiveness ratio of €10,847 (GBP7445) per
QALY and €32,151 (GBP22,066) per QALY for all types of frac-
tures. CONCLUSIONS: From a payer’s perspective, rhBMP-2 is
a cost-saving treatment option in grade III open tibia fractures
for the German and French health care systems and cost-effec-
tive for all grades of open tibia fractures in Germany, UK, and
France.
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Cost-effectiveness model was adopted to the Hungarian health
care settings in order to evaluate the costs, effectiveness and cost-
effectiveness of two years comparison of zoledronic acid therapy
(5 mg infusion over 15 minutes given once) with risedronate
therapy (30 mg/day orally given for 2 months), alendronate
therapy (40 mg/day orally given for 6 months), tiludronate
therapy (400 mg/day orally given for 3 months) and pamidronate
therapy (180 mg I.V. in 6 weeks) in patients with Paget’s disease
of bone. The long term outcome was evaluated by the cost per
time in response over two years period. The measure of effect
the time patients are in response was based on SAP measure-
ment. Data sources were randomized clinical trials of treatments
in PDB, literature and expert opinion. The analysis was per-
formed from a society perspective. Discounting rate of 6% was
applied for costs and effects in the second year. A standard
costing methodology was used, according to the patterns of care
currently in use in Hungary. Costs were calculated to cover
medical procedures performed in two years time frame for
patients with PDB and include direct costs of treatment and
follow-up (visit to physicians ofﬁces, prescription of medication,
laboratory procedures and treatment costs of side effects. As a
result zoledronic acid dominated all the other therapies com-
pared, hence it was the most effective and the least expensive in
the treatment of Paget’s disease of bone.
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OBJECTIVES: Oral bisphosphonate treatment is standard
therapy for PMO, but certain patients are unsuitable for this
therapy due to intolerance or dosing difﬁculties. Such patients
may receive “off-label” unlicensed IV bisphosphonates, typically
IV pamidronate in the UK. Ibandronate is the ﬁrst IV prepara-
tion licensed for PMO and this study provides an economic
analysis of IV ibandronate in this setting. METHODS: IV iban-
dronate is administered as a 3 mg IV “push” lasting 15–30
seconds every 3 months, and priced approximately £27/mg. IV
pamidronate (30–60 mg) is infused (10–60 mg/hour) every 3
months, and priced at approximately £2/mg across the prepara-
tions available. A cost-minimisation analysis was undertaken to
demonstrate the economic case for IV ibandronate, since based
on a review of the clinical evidence base and licensing status, IV
ibandronate is assumed to provide at least as much clinical
beneﬁt as IV pamidronate. This analysis included referenced
NHS costs for drug acquisition and administration (pharmacy
preparation, disposables and nurse time required for infusions/IV
administration) and compared IV ibandronate to the “average”
use of IV pamidronate—45 mg infused at 20 mg/hour. Due to the
range of doses and infusion types used for IV pamidronate, sen-
sitivity analyses were conducted. RESULTS: Ibandronate is cost-
saving on acquisition (£18/patient/year) and particularly on
administration (£407/patient/year). The total cost-saving associ-
ated with a switch from pamidronate to ibandronate is approx-
imately £425/patient/year and driven primarily by lower
administration costs. Under sensitivity analysis, ibandronate
remains cost-saving even when the comparator is generic 30 mg
pamidronate, pamidronate is infused at the maximum rate, or
when nurses manage several patients’ infusions simultaneously.
CONCLUSIONS: Ibandronate IV injection is cost-saving for the
NHS compared to IV pamidronate infusion, under a range of
realistic scenarios. When this ﬁnding is considered alongside IV
ibandronate’s evidence base and licence for PMO, it is concluded
that ibandronate IV injection clearly offers value for money.
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OBJECTIVES: Treatment of post-menopausal osteoporosis with
bisphosphonates should be supplemented by adequate amounts
of calcium. The objective of this analysis was to assess the cost-
effectiveness of the combination package of risedronate plus
calcium compared to generic alendronate and calcium sup-
plements in high-risk osteoporotic patients in Germany.
METHODS: A validated model (Tosteson, 2001) was used to
estimate the impact of therapy on hip and vertebral fractures,
costs, and quality adjusted life years (QALYs). The analysis
included women 70 years with a BMD T-Score of <−2.5 and a
history of vertebral fracture, treated over 3 years. The model
further simulated downstream costs and QALYs for a 10-year
period. Country-speciﬁc data included general population mor-
tality, hip and hospitalized vertebral fracture rates, fracture costs,
and annual drug costs (risedronate plus calcium €547.76; generic
alendronate €411.23; calcium €59.50). Hip and vertebral frac-
ture reductions for risedronate were 60% (McClung, Geusens,
Miller, 2001) and 49% (Reginster, Minne, Sorenson, 2000)
respectively; and for alendronate were 51% and 47% (Black,
Cummings, Karpf, 1996) respectively. RESULTS: In a cohort of
1000 postmenopausal women with 3 years of treatment the
model predicted the following costs of €8.42M versus €8.40M,
total hip and hospitalized vertebral fractures of 140 versus 143
and QALYs of 6168 versus 6164 for risedronate plus calcium
and generic alendronate plus calcium, respectively. Risedronate
plus calcium was more cost-effective than generic alendronate
plus calcium, with a cost per fracture averted of €8764 and a
cost per QALY gained of €8698. CONCLUSIONS: The analysis
favors the adoption of risedronate plus calcium therapy for the
treatment of postmenopausal osteoporosis compared to generic
alendronate plus calcium.
